SCHEMBL17820115

SCHEMBL17820115

O=C(O)Nc1ccc2c(c1)Oc1c(Br)cccc1C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 2/20 0.37
ADRA2A P08913 1/20 0.37
MAOA P21397 1/20 0.37
SLC6A2 P23975 1/20 0.37
HTR2C P28335 1/20 0.37
SLC6A4 P31645 1/20 0.37
HTR2B P41595 1/20 0.37
NPC1 O15118 8/20 0.37
CYP3A4 P08684 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPK1 P28482 2/20 0.36
KDM4E B2RXH2 2/20 0.36
PPARG P37231 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17820794 0.90 RAB9A (0.39) RAB9ASMN1; SMN2CASP3SENP7SENP6
SCHEMBL17827852 0.83 NR1I3 (0.41) RAB9ANPC1MEN1KMT2ACA12
SCHEMBL17819791 0.82 NPC1 (0.37) RAB9ASMN1; SMN2CASP3SENP7SENP6
SCHEMBL17820007 0.82 TRPM8 (0.40) RAB9ASMN1; SMN2NPC1TRPM8TP53
SCHEMBL22412944 0.82 POLB (0.45) RAB9ASMN1; SMN2CYP1A2ADRA2AMAOA
SCHEMBL17820895 0.77 CYP1A2 (0.34) RAB9ACYP1A2ADRA2AMAOASLC6A2
SCHEMBL17820806 0.75 MEN1 (0.40) RAB9ANPC1KDM4ETSHRPOLB
SCHEMBL17820428 0.74 MAPT (0.41) RAB9ASMN1; SMN2MAOANPC1KDM4E
SCHEMBL17820170 0.73 RAB9A (0.40) RAB9ASMN1; SMN2CASP3SENP7SENP6
SCHEMBL17819807 0.72 SLC1A3 (0.37) RAB9ASMN1; SMN2CASP3SENP7SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3042900-B1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2020-09-23 EP disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
EP-3042900-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF Fujifilm Corporation (JP) 2016-07-13 EP disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF PRMT7, RBBP7, RER1 RAB9A 757/4885SMN1; SMN2 1734/4885CASP3 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.